Cargando…

CMHX008, a PPARγ partial agonist, enhances insulin sensitivity with minor influences on bone loss

Traditional thiazolidinediones (TZDs), such as rosiglitazone, are peroxisome proliferator-activated receptor γ (PPARγ) potent agonists that can be used to treat type 2 diabetes but carry unwanted effects, including increased risk for fracture. The present work aimed to compare the insulin-sensitizin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hou, Yi, Cao, Xuemei, Hu, Xiangnan, Li, Xinyu, Shi, Xiaoqin, Wang, Hongying, Peng, Chuan, Li, Jiayu, Li, Jibin, Li, Qifu, Wu, Chaodong, Xiao, Xiaoqiu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Chongqing Medical University 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6176219/ https://www.ncbi.nlm.nih.gov/pubmed/30320193 http://dx.doi.org/10.1016/j.gendis.2018.05.004

Ejemplares similares

CMHX008, a Novel Peroxisome Proliferator-Activated Receptor γ Partial Agonist, Enhances Insulin Sensitivity In Vitro and In Vivo
por: Ming, Yue, et al.
Publicado: (2014)

Ectopic Overexpression of PPARγ2 in the Heart Determines Differences in Hypertrophic Cardiomyopathy After Treatment With Different Thiazolidinediones in a Mouse Model of Diabetes
por: Cao, Xuemei, et al.
Publicado: (2021)

Hippocampal overexpression of TREM2 ameliorates high fat diet induced cognitive impairment and modulates phenotypic polarization of the microglia
por: Wu, Min, et al.
Publicado: (2020)

PPAR-γ Partial Agonists in Disease-Fate Decision with Special Reference to Cancer
por: Ballav, Sangeeta, et al.
Publicado: (2022)

Scaffold-Based Pan-Agonist Design for the PPARα, PPARβ and PPARγ Receptors
por: Zhang, Li-Song, et al.
Publicado: (2012)

Anti-Diabetic Effect of Telmisartan Through its Partial PPARγ-Agonistic Activity
por: Ayza, Muluken Altaye, et al.
Publicado: (2020)

The roles of PPARγ and its agonists in autoimmune diseases: A comprehensive review
por: Liu, Yu, et al.
Publicado: (2020)

Structure-Based Virtual Screening and Discovery of New PPARδ/γ Dual Agonist and PPARδ and γ Agonists
por: Maltarollo, Vinicius G., et al.
Publicado: (2015)

Neuroprotective Properties of a Novel Non-Thiazoledinedione Partial PPAR-γ Agonist against MPTP
por: Swanson, Christine R., et al.
Publicado: (2013)

Structural and Dynamic Elucidation of a Non-acid PPARγ Partial Agonist: SR1988
por: Frkic, Rebecca L., et al.
Publicado: (2018)

Medium Chain Fatty Acids Are Selective Peroxisome Proliferator Activated Receptor (PPAR) γ Activators and Pan-PPAR Partial Agonists
por: Liberato, Marcelo Vizoná, et al.
Publicado: (2012)

PPARγ Agonists: Blood Pressure and Edema
por: Blazer-Yost, Bonnie L.
Publicado: (2010)

PPARγ Agonists: Emergent Therapy in Endometriosis
por: Vallée, Alexandre, et al.
Publicado: (2021)

Novel Podophyllotoxin Derivatives as Partial PPARγ Agonists and their Effects on Insulin Resistance and Type 2 Diabetes
por: Zhang, Xiangming, et al.
Publicado: (2016)

Novel Benzylidene Thiazolidinedione Derivatives as Partial PPARγ Agonists and their Antidiabetic Effects on Type 2 Diabetes
por: Yasmin, Sabina, et al.
Publicado: (2017)

Comparative Gene Expression Profiles Induced by PPARγ and PPARα/γ Agonists in Human Hepatocytes
por: Rogue, Alexandra, et al.
Publicado: (2011)

PPARγ Agonists: Potential as Therapeutics for Neovascular Retinopathies
por: Pershadsingh, Harrihar A., et al.
Publicado: (2008)

The Role of PPARγ in the Transcriptional Control by Agonists and Antagonists
por: Tsukahara, Tamotsu
Publicado: (2012)

PPARγ Agonist Beyond Glucose Lowering Effect
por: Sugawara, Akira, et al.
Publicado: (2011)

Relaxation of human pulmonary arteries by PPARγ agonists
por: Kozłowska, Hanna, et al.
Publicado: (2013)

Biological Rationale for the Use of PPARγ Agonists in Glioblastoma
por: Ellis, Hayley Patricia, et al.
Publicado: (2014)

PPAR-γ Agonists and Their Role in Primary Cicatricial Alopecia
por: Harnchoowong, Sarawin, et al.
Publicado: (2017)

PPARγ and Its Agonists in Chronic Kidney Disease
por: Ma, Yuhua, et al.
Publicado: (2020)

Expression of peroxisome proliferator-activated receptor (PPAR)γ in gastric cancer and inhibitory effects of PPARγ agonists
por: Sato, H, et al.
Publicado: (2000)

Development of an In Vitro Screening Platform for the Identification of Partial PPARγ Agonists as a Source for Antidiabetic Lead Compounds
por: Porskjær Christensen, Lars, et al.
Publicado: (2018)

Chiral phenoxyacetic acid analogues inhibit colon cancer cell proliferation acting as PPARγ partial agonists
por: Sabatino, Lina, et al.
Publicado: (2019)

Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)α agonist fenofibrate and the PPARγ agonist pioglitazone
por: Syversen, Unni, et al.
Publicado: (2009)

MBX-102/JNJ39659100, a Novel Non-TZD Selective Partial PPAR-γ Agonist Lowers Triglyceride Independently of PPAR-α Activation
por: Chandalia, Apurva, et al.
Publicado: (2009)

Structural Basis for PPARs Activation by The Dual PPARα/γ Agonist Sanguinarine: A Unique Mode of Ligand Recognition
por: Tian, Siyu, et al.
Publicado: (2021)

Pseudoginsenoside F11, a Novel Partial PPARγ Agonist, Promotes Adiponectin Oligomerization and Secretion in 3T3-L1 Adipocytes
por: Wu, Guoyu, et al.
Publicado: (2013)

PPAR-γ Thiazolidinedione Agonists and Immunotherapy in the Treatment of Brain Tumors
por: Lichtor, Terry, et al.
Publicado: (2008)

New Insights into the PPARγ Agonists for the Treatment of Diabetic Nephropathy
por: Jia, Zhanjun, et al.
Publicado: (2014)

Therapeutic potential of PPARγ natural agonists in liver diseases
por: Wu, Liwei, et al.
Publicado: (2020)

Dual PPAR α/γ Agonists: Continuing Cardiac Concerns
por: Balachandran, Karthik
Publicado: (2019)

The PPARγ Agonist Rosiglitazone Enhances the Radiosensitivity of Human Pancreatic Cancer Cells
por: Wang, Zhenyu, et al.
Publicado: (2020)

PPARγ agonists delay age‐associated metabolic disease and extend longevity
por: Xu, Lingyan, et al.
Publicado: (2020)

Partial Agonist, Telmisartan, Maintains PPARγ Serine 112 Phosphorylation, and Does Not Affect Osteoblast Differentiation and Bone Mass
por: Kolli, Vipula, et al.
Publicado: (2014)

Synthesis and biological evaluation of dihydropyrano-[2,3-c]pyrazoles as a new class of PPARγ partial agonists
por: Qvortrup, Katrine, et al.
Publicado: (2017)

Synthesis, molecular docking, and in vivo antidiabetic evaluation of new benzylidene-2,4-thiazolidinediones as partial PPAR-γ agonists
por: Najmi, Asim, et al.
Publicado: (2023)

Identification of a Novel PPAR-γ Agonist through a Scaffold Tuning Approach
por: Gim, Hyo Jin, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_tqpm190jgtrv4d62pp8n5kbl9t